查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1445541

前列腺癌诊断市场评估：诊断技术、癌症类型、最终用户和地区的机会和预测（2017-2031）

Prostate Cancer Diagnostics Market Assessment, By Diagnostic Technique, By Cancer Type, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 227 Pages | 商品交期: 3-5个工作天内

价格

全球摄护腺癌诊断市场规模将从2023年的63.1亿美元成长到2031年的110.5亿美元，2024-2031年预测期间内复合年增长率为7.26%，预计规模将持续成长。

全球前列腺癌诊断市场受到多种因素的影响。 这包括人工智慧等技术的进步、投资的增加、生物标记测试的主导地位、腺癌诊断工具以及对前列腺癌认识的提高。

技术进步

人工智慧和其他技术的进步正在对全球前列腺癌诊断市场的扩张产生重大影响。 人工智慧在诊断中的应用提高了前列腺癌的检测效率和准确性。 透过检查大型资料集，人工智慧演算法可以检测人眼可能看不见的前列腺癌的特定迹象。 这使得人工智慧演算法能够比传统策略更快、更好地诊断癌症。 这种能力对于早期预后至关重要，因为它可以及时进行干预。 人工智慧的使用正在彻底改变前列腺癌诊断领域，改善患者治疗效果并加速公司发展。

增加投资

全球前列腺癌诊断市场由公司和组织资助，以鼓励创造新想法。 需要获得资金来开发检测前列腺癌的新策略和加强研发工作的技术。 目前正在进行投资以支援新方法的开发和现有方法的改进，例如人工智慧驱动的诊断平台和先进的生物标记测试，这将在推动行业向前发展方面发挥关键作用。我是。 增加投资将刺激创新，并有助于摆脱过时的前列腺癌诊断技术。

生物标记测试的优点

前列腺癌诊断的急剧增加主要是由于对生物标记测试的需求不断增加。 生物标记测试是最常用的技术，并且由于其许多优点而变得越来越受欢迎。 这些测试灵敏且特异，可以识别与前列腺癌相关的蛋白质和基因。 由于可以立即治疗，因此甚至可以在症状出现之前进行早期发现。 此外，生物标记测试可以提供有关癌症侵袭性和治疗反应性的重要资讯，从而製定量身定制的治疗策略。 需求的增加是由于前列腺癌检测和治疗的生物标记测试的效率和准确性。

腺癌诊断工具

由于引入了旨在检测各种形式的前列腺癌（尤其是流行的腺癌）的创新设备，全球前列腺癌诊断市场正在经历快速增长。 这些仪器利用最先进的技术，包括分子诊断和先进成像，来准确识别和表征腺癌。 这是一个主要的临床优势。 有了有关肿瘤位置、大小和范围的详细信息，医生可以製定高度针对性的治疗计划，以优化患者的治疗效果。 这些专门的诊断工具满足了早期准确检测的迫切需求，被认为是成功治疗前列腺癌的基石。

本报告调查了全球前列腺癌诊断市场，提供了市场定义和概述、市场规模趋势和预测、各个细分市场和地区的详细分析、行业结构以及影响市场成长的因素。我们编制分析、案例研究、竞争景观、主要公司简介等等。

目录

第 1 章研究方法

第 2 章专案范围与定义

第 3 章执行摘要

第 4 章全球前列腺癌诊断市场展望

  • 市场规模/预测
  • 透过诊断技术
    • 影像检查
    • 切片
    • 生物标记测试
    • 免疫组织化学
    • 其他
  • 依癌症类型
    • 鳞状细胞癌
    • 小细胞前列腺癌
    • 腺癌
    • 移行细胞癌
    • 其他
  • 按最终用户
    • 医院
    • 癌症研究所
    • 诊断中心
    • 其他
  • 按地区
    • 北美
    • 欧洲
    • 亚太地区
    • 南美洲
    • 中东/非洲
  • 各公司的市占率

第 5 章全球前列腺癌诊断市场展望：按地区

  • 北美
  • 欧洲
  • 亚太地区
  • 南美洲
  • 中东/非洲

第 6 章市场映射

  • 透过诊断技术
  • 依癌症类型
  • 按最终用户
  • 按地区

第 7 章宏观环境与产业结构

  • 需求与供给分析
  • 汇入/汇出分析
  • 价值链分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市场动态

  • 生长促进因素
  • 生长抑制因素（问题、限制因素）

第 9 章监理架构与创新

  • 临床试验
  • 专利情况
  • 监理机关的核准
  • 创新/新兴技术

第 10 章主要公司状况

  • 前 5 名市场领导者的竞争矩阵
  • 前 5 位市场领导者的市场收入分析
  • 併购/合资企业（如果适用）
  • SWOT 分析（5 家参与公司）
  • 专利分析（如果适用）

第 11 章价格分析

第 12 章案例研究

第 13 章主要公司展望

  • Roche Holdings AG
  • Siemens Healthineers AG
  • Myriad Genetics, Inc.
  • Thermo Fisher Scientific Inc.
  • Becton Dickinson and Company
  • AstraZeneca plc
  • F. Hoffmann-La Roche Ltd.
  • Koninklijke Philips N.V.
  • Biocept Inc
  • Agilent Technologies, Inc.

第 14 章策略建议

第 15 章关于我们公司/免责声明

Product Code: MX11090

Global prostate cancer diagnostics market is projected to witness a CAGR of 7.26% during the forecast period 2024-2031, growing from USD 6.31 billion in 2023 to USD 11.05 billion in 2031. The global prostate cancer diagnostics market is shaped by various factors. These include advancing technologies such as AI, an increase in investments, advantages of biomarker test offerings, tools for diagnosis of adenocarcinoma, and a rise in awareness of prostate cancer.

These factors are crucial for the growth and development of the market. Advancements in cutting-edge technologies, especially artificial intelligence (AI), play an important role in influencing the global prostate cancer diagnostics market. AI is responsible for the increasing speed and accuracy of diagnosis by analyzing large amounts of complex data for patterns that indicate prostate cancer.

Both public and private firms are heavily investing in the global prostate cancer diagnostics market. These investments are used for research and development purposes, which help in developing advanced solutions for the market. Often, public and private firms work together utilizing each other's strengths to spur innovation in the global prostate cancer diagnostics market. Hence, public private partnerships are often a successful model in the healthcare industry.

Another important aspect influencing the global prostate cancer diagnostics market is biomarker testing. By detecting a chemical in blood or tissue, biomarker testing provides important information that helps clinicians to make a diagnosis. Thus, due to the accuracy and reliability provided by biomarkers, they are considered important devices for early detection and monitoring of prostate cancer.

Significant developments have been made in the improvement of specialized instruments meant for the diagnosis of adenocarcinoma, the most common form of prostate cancer. By using these instruments, malignant cells in the prostate may be exactly identified and defined, taking into consideration extra-centered and successful remedy plans. It is a significant factor influencing the growth of global prostate cancer diagnostics market.

Consequently, there has been a tremendous impact from the increased expertise in prostate cancer. Higher screening quotes, early detection, and better remedy outcomes have resulted from elevated widespread public expertise and comprehension of the disorder. For instance, Astellas, a Japanese multinational pharmaceutical company, provided financing support for the Prostate Health Awareness and Screening Campaign (PHASC) in June 2023 with the support of MAP International. It is a multifaceted strategy aimed at increasing public knowledge of a malignancy that has been historically underrepresented in the Dominican Republic through the media.

Technological Advancements

The expansion of global prostate cancer diagnostics market is being significantly affected by advancing technologies specifically AI. The use of AI in diagnostic methods improves prostate cancer detection efficiency and accuracy. AI algorithms can detect certain signs of prostate cancer that may go unnoticed by the human eye by examining big datasets. It permits AI algorithms to diagnose cancer more quickly and appropriately than traditional strategies. The capability is crucial for early prognosis since it makes timely interventions that might save lives. As a result, using AI is causing a revolution inside the field of prostate cancer diagnostics, improving affected person outcomes and accelerating enterprise expansion.

Researchers at the UCLA Health Jonsson Comprehensive Cancer Center were awarded a three-year, USD 3 million grant by the National Cancer Institute in December 2023 to help prevent needless treatments and their unfavorable side effects. The goal of this grant is to identify novel cancer biomarkers and develop AI that can detect and predict aggressive prostate cancer.

Increase in Investments

The global prostate cancer diagnostics market receives funding from businesses and organizations to encourage the creation of new ideas. Access to funding is necessary to enable the development of new strategies for the detection of prostate cancer and technologies to enhance research and development efforts. Investments are being made to help develop new methods and improve upon existing methods, such as AI-powered diagnostic platforms and sophisticated biomarker tests which play an important role in driving the industry forward. Increased investments spur innovation and help in getting rid of the age-old technologies for diagnosing prostate cancer.

On 13th February, Macmillan Cancer Support announced their investment of GBP 350,100 in Pi, Lucida Medical's new AI platform, to improve the accuracy and efficiency of prostate cancer tests.

Advantages that the Biomarker Test Offers

Prostate cancer diagnosis is increasing exponentially mainly due to the growing demand for biomarker testing. Biomarker tests are the most commonly used methods and are becoming increasingly popular due to their numerous advantages. As these tests are highly sensitive and specific, they can identify the proteins or genes associated with prostate cancer. It allows for an immediate response that allows for early detection of the condition, even before symptoms appear. In addition, biomarker testing may enable the development of tailored treatment strategies by providing important information about cancer aggressiveness and responsiveness to treatment. Increasing demand is due to the efficiency and accuracy of biomarker testing for the detection and treatment of prostate cancer, emphasizing its importance in the global prostate cancer diagnostics market.

In July 2023, Quest Diagnostics announced the introduction of AmeriPath, a new prostate cancer biomarker test in association with Envision Sciences, which is its subspecialty pathology division. Envision Sciences Pty Ltd. is creating a pipeline of blood and tissue biomarker-based cancer diagnostic and predictive assays.

Tools for Diagnosis of Adenocarcinoma

The global prostate cancer diagnostics market is experiencing a surge, driven by the introduction of innovative instruments designed to detect its diverse forms, particularly the prevalent adenocarcinoma. These instruments leverage cutting-edge technologies like molecular diagnostics and advanced imaging, offering precise identification and characterization of adenocarcinomas. It translates to a significant clinical advantage. Armed with detailed information on tumor location, size, and extent, physicians can formulate highly targeted treatment plans, optimizing patient outcomes. These specialized diagnostic tools address a critical need for early and accurate detection, considered as a cornerstone of successful prostate cancer management.

Consequently, the launch of these instruments represents a strategic market mover, catering to the burgeoning demand for sophisticated diagnostic solutions. The development benefits patients through improved clinical outcomes and propels the industry forward by addressing a crucial unmet need. The advancements signify a positive trajectory for the prostate cancer diagnostics market, paving the way for enhanced patient care and industry growth.

Prostate cancer may be diagnosed by pathologists using QAi Prostate, a sophisticated artificial intelligence (AI) technology that was unveiled in March 2023 by Singapore-based healthtech startup Qritive. QAi Prostate uses sophisticated machine learning (ML) algorithms to reliably identify regions of prostatic adenocarcinoma and classify benign and malignant tumor locations in biopsy tissue samples.

North America to Dominate the Market

North America stands as the leader in the global prostate cancer diagnostics market. The region is expected to dominate due to its advanced healthcare system and the concerning rates of disease in specific populations. The region boasts a sophisticated healthcare infrastructure that fosters exhilarating innovation. It translates to intensified research, development, and adoption of cutting-edge diagnostic technologies, propelling the market forward at a rapid pace. Powerful tools like molecular diagnostics and advanced imaging empower early detection and more precise diagnosis. Also, the need for these advancements resonates deeply in communities disproportionately affected by the disease. Native American and Black men face alarmingly high prostate cancer rates, highlighting the urgent need for effective diagnostic methods. In North Carolina, prostate cancer sits as the second-highest cause of male cancer deaths, further underlining the criticality of early identification.

An interactive web application was introduced in December 2023 by Carolina Demography and The UNC Men's Health Programme to eliminate prostate cancer inequities in North Carolina and increase public awareness of the disease.

Future Market Scenario

Introduction of new biomarkers such as 4Kscore, TMPRSS2-ERG fusion, and PCA3 to diagnose prostate cancer correctly and with improved efficiency to spur the global prostate cancer diagnostics market in the future.

The increasing number of cases of adenocarcinoma will drive the growth of the global prostate cancer diagnostics market.

Patients preferring more cost-effective and personalized treatment options in the global prostate cancer diagnostics market will force the healthcare industry to adapt to more faster and convenient methods of diagnosis.

With new startups entering the global prostate cancer diagnostics market, there will be an outburst of new technological interventions to diagnose prostate cancer.

Key Players Landscape and Outlook

The global prostate cancer diagnostics market is witnessing a significant shift towards strategic partnerships between startups and small businesses. The collaborative approach allows these entities to surmount financial and technological hurdles that might otherwise impede their independent progress. By pooling resources, knowledge, and cutting-edge technologies, these alliances can significantly accelerate research and development activities, leading to the emergence of innovative diagnostic tools and techniques. Such partnerships create a dynamic and competitive market environment, fostering a culture of continuous innovation. The diversity of ideas and expertise brought together by these partnerships results in a broader spectrum of diagnostic solutions.

Leading AI-powered biopharmaceutical company BPGbio, Inc. has partnered with Grupo Terralpe, Inc. in July 2023. The businesses will collaborate to market BPGbio's prostate cancer diagnostic test, pstateDx, in Mexico.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Prostate Cancer Diagnostics Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. By Diagnostic Technique
    • 4.2.1. Imaging Tests
      • 4.2.1.1. Ultrasound
      • 4.2.1.2. Positron Emission Tomography (PET) Scan
      • 4.2.1.3. Magnetic Resonance Imaging (MRI)
      • 4.2.1.4. Computerized Tomography (CT) Scan
      • 4.2.1.5. Bone Scan
    • 4.2.2. Biopsy
    • 4.2.3. Biomarker Tests
    • 4.2.4. Immunohistochemistry
    • 4.2.5. Others
  • 4.3. By Cancer Type
    • 4.3.1. Squamous Cell Carcinoma
    • 4.3.2. Small Cell Prostate Cancer
    • 4.3.3. Adenocarcinoma
    • 4.3.4. Transitional Cell Carcinoma
    • 4.3.5. Others
  • 4.4. By End-user
    • 4.4.1. Hospitals
    • 4.4.2. Cancer Research Institutes
    • 4.4.3. Diagnostic Centers
    • 4.4.4. Others
  • 4.5. By Region
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia-Pacific
    • 4.5.4. South America
    • 4.5.5. Middle East and Africa
  • 4.6. By Company Market Share (%), 2023

5. Global Prostate Cancer Diagnostics Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. By Value
      • 5.1.1.2. By Volume
    • 5.1.2. By Diagnostic Technique
      • 5.1.2.1. Imaging Tests
      • 5.1.2.1.1. Ultrasound
      • 5.1.2.1.2. Positron Emission Tomography (PET) Scan
      • 5.1.2.1.3. Magnetic Resonance Imaging (MRI)
      • 5.1.2.1.4. Computerized Tomography (CT) Scan
      • 5.1.2.1.5. Bone Scan
      • 5.1.2.2. Biopsy
      • 5.1.2.3. Biomarker Tests
      • 5.1.2.4. Immunohistochemistry
      • 5.1.2.5. Others
    • 5.1.3. By Cancer Type
      • 5.1.3.1. Squamous Cell Carcinoma
      • 5.1.3.2. Small Cell Prostate Cancer
      • 5.1.3.3. Adenocarcinoma
      • 5.1.3.4. Transitional Cell Carcinoma
      • 5.1.3.5. Others
    • 5.1.4. By End-user
      • 5.1.4.1. Hospitals
      • 5.1.4.2. Cancer Research Institutes
      • 5.1.4.3. Diagnostic Centers
      • 5.1.4.4. Others
    • 5.1.5. United States*
      • 5.1.5.1. Market Size & Forecast
      • 5.1.5.1.1. By Value
      • 5.1.5.1.2. By Volume
      • 5.1.5.2. By Diagnostic Technique
      • 5.1.5.2.1. Imaging Tests
      • 5.1.5.2.1.1. Ultrasound
      • 5.1.5.2.1.2. Positron Emission Tomography (PET) Scan
      • 5.1.5.2.1.3. Magnetic Resonance Imaging (MRI)
      • 5.1.5.2.1.4. Computerized Tomography (CT) Scan
      • 5.1.5.2.1.5. Bone Scan
      • 5.1.5.2.2. Biopsy
      • 5.1.5.2.3. Biomarker Tests
      • 5.1.5.2.4. Immunohistochemistry
      • 5.1.5.2.5. Others
      • 5.1.5.3. By Cancer Type
      • 5.1.5.3.1. Squamous Cell Carcinoma
      • 5.1.5.3.2. Small Cell Prostate Cancer
      • 5.1.5.3.3. Adenocarcinoma
      • 5.1.5.3.4. Transitional Cell Carcinoma
      • 5.1.5.3.5. Others
      • 5.1.5.4. By End-user
      • 5.1.5.4.1. Hospitals
      • 5.1.5.4.2. Cancer Research Institutes
      • 5.1.5.4.3. Diagnostic Centers
      • 5.1.5.4.4. Others
    • 5.1.6. Canada
    • 5.1.7. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Diagnostic Technique
  • 6.2. By Cancer Type
  • 6.3. By End-user
  • 6.4. By Region

7. Macro Environment and Industry Structure

  • 7.1. Demand Supply Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Clinical Trials
  • 9.2. Patent Landscape
  • 9.3. Regulatory Approvals
  • 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Roche Holdings AG
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Siemens Healthineers AG
  • 13.3. Myriad Genetics, Inc.
  • 13.4. Thermo Fisher Scientific Inc.
  • 13.5. Becton Dickinson and Company
  • 13.6. AstraZeneca plc
  • 13.7. F. Hoffmann-La Roche Ltd.
  • 13.8. Koninklijke Philips N.V.
  • 13.9. Biocept Inc
  • 13.10. Agilent Technologies, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 2. Global Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 3. Global Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 4. Global Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 5. Global Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 6. Global Prostate Cancer Diagnostics Market Share (%), By Region, 2017-2031F
  • Figure 7. North America Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 8. North America Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 9. North America Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 10. North America Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 11. North America Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 12. North America Prostate Cancer Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 13. United States Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 14. United States Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 15. United States Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 16. United States Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 17. United States Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 18. Canada Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 19. Canada Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 20. Canada Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 21. Canada Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 22. Canada Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 23. Mexico Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 24. Mexico Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 25. Mexico Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 26. Mexico Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 27. Mexico Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 28. Europe Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 29. Europe Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 30. Europe Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 31. Europe Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 32. Europe Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 33. Europe Prostate Cancer Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 34. Germany Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 35. Germany Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 36. Germany Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 37. Germany Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 38. Germany Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 39. France Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 40. France Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 41. France Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 42. France Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 43. France Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 44. Italy Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 45. Italy Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 46. Italy Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 47. Italy Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 48. Italy Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 49. United Kingdom Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 50. United Kingdom Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 51. United Kingdom Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 52. United Kingdom Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 53. United Kingdom Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 54. Russia Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 55. Russia Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 56. Russia Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 57. Russia Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 58. Russia Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 59. Netherlands Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 60. Netherlands Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 61. Netherlands Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 62. Netherlands Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 63. Netherlands Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 64. Spain Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 65. Spain Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 66. Spain Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 67. Spain Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 68. Spain Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 69. Turkey Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 70. Turkey Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 71. Turkey Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 72. Turkey Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 73. Turkey Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 74. Poland Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 75. Poland Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 76. Poland Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 77. Poland Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 78. Poland Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 79. South America Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 80. South America Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 81. South America Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 82. South America Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 83. South America Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 84. South America Prostate Cancer Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 85. Brazil Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 86. Brazil Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 87. Brazil Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 88. Brazil Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 89. Brazil Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 90. Argentina Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 91. Argentina Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 92. Argentina Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 93. Argentina Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 94. Argentina Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 95. Asia-Pacific Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 96. Asia-Pacific Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 97. Asia-Pacific Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 98. Asia-Pacific Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 99. Asia-Pacific Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 100. Asia-Pacific Prostate Cancer Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 101. India Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 102. India Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 103. India Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 104. India Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 105. India Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 106. China Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 107. China Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 108. China Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 109. China Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 110. China Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 111. Japan Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 112. Japan Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 113. Japan Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 114. Japan Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 115. Japan Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 116. Australia Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 117. Australia Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 118. Australia Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 119. Australia Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 120. Australia Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 121. Vietnam Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 122. Vietnam Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 123. Vietnam Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 124. Vietnam Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 125. Vietnam Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 126. South Korea Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 127. South Korea Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 128. South Korea Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 129. South Korea Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 130. South Korea Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 131. Indonesia Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 132. Indonesia Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 133. Indonesia Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 134. Indonesia Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 135. Indonesia Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 136. Philippines Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 137. Philippines Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 138. Philippines Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 139. Philippines Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 140. Philippines Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 141. Middle East & Africa Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 142. Middle East & Africa Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 143. Middle East & Africa Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 144. Middle East & Africa Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 145. Middle East & Africa Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 146. Middle East & Africa Prostate Cancer Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 147. Saudi Arabia Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 148. Saudi Arabia Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 149. Saudi Arabia Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 150. Saudi Arabia Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 151. Saudi Arabia Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 152. UAE Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 153. UAE Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 154. UAE Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 155. UAE Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 156. UAE Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 157. South Africa Prostate Cancer Diagnostics Market, By Value, in USD Billion, 2017-2031F
  • Figure 158. South Africa Prostate Cancer Diagnostics Market, By Volume, in Thousand Units, 2017-2031F
  • Figure 159. South Africa Prostate Cancer Diagnostics Market Share (%), By Diagnostic Technique, 2017-2031F
  • Figure 160. South Africa Prostate Cancer Diagnostics Market Share (%), By Cancer Type, 2017-2031F
  • Figure 161. South Africa Prostate Cancer Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 162. By Diagnostic Technique Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 163. By Cancer Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 164. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 165. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023